ANI Pharmaceuticals (NASDAQ:ANIP) SVP Ori Gutwerg Sells 2,060 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total transaction of $157,590.00. Following the completion of the transaction, the senior vice president owned 84,782 shares in the company, valued at approximately $6,485,823. This trade represents a 2.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

ANI Pharmaceuticals Trading Up 0.6%

Shares of ANIP stock traded up $0.43 during mid-day trading on Wednesday, reaching $76.53. The company’s stock had a trading volume of 676,665 shares, compared to its average volume of 333,651. ANI Pharmaceuticals, Inc. has a 12-month low of $56.71 and a 12-month high of $99.50. The firm has a market capitalization of $1.72 billion, a PE ratio of 22.78 and a beta of 0.52. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. The company’s 50 day simple moving average is $79.92 and its 200-day simple moving average is $86.11.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after buying an additional 237 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the first quarter worth about $28,000. Newbridge Financial Services Group Inc. grew its holdings in ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after acquiring an additional 400 shares during the period. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals in the fourth quarter worth about $48,000. Finally, State of Wyoming acquired a new stake in ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. 76.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ANIP shares. Barclays initiated coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Finally, Guggenheim increased their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $103.43.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.